Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9052759rdf:typepubmed:Citationlld:pubmed
pubmed-article:9052759lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:9052759lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:9052759lifeskim:mentionsumls-concept:C1336575lld:lifeskim
pubmed-article:9052759lifeskim:mentionsumls-concept:C1513095lld:lifeskim
pubmed-article:9052759lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:9052759lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:9052759lifeskim:mentionsumls-concept:C0597880lld:lifeskim
pubmed-article:9052759lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:9052759pubmed:issue5lld:pubmed
pubmed-article:9052759pubmed:dateCreated1997-3-20lld:pubmed
pubmed-article:9052759pubmed:abstractTextTAP1 and TAP2 molecules are involved in the transport of peptides prior to their association with class I molecules and are mandatory for efficient antigen presentation. To investigate whether loss of expression of TAP1 or TAP2 is a likely mechanism of immune escape in malignant melanoma, TAP1 and TAP2 mRNA was analyzed by RT-PCR in 39 melanoma cell lines expressing at least 2 of the known melanoma-associated antigens, tyrosinase, Melan-A/MART-1, gp100, MAGE-1 and MAGE-3. All 39 cell lines expressed both TAP1 and TAP2 at the mRNA level. To investigate other factors potentially involved in immune escape, the expression of LMP2, LMP7, HLA class I molecules, beta2-microglobulin (beta2m) and specific HLA-A alleles was evaluated by RT-PCR and FACS analyses. All 39 cell lines expressed LMP2, LMP7 and beta2m. A single cell line (FM37) had lost the expression of class I molecules, and this same cell line showed loss of expression of the HLA-A2 heavy chain. No cell lines showed loss of expression of the HLA-A1 heavy chain. Based on our studies of in vitro established cell lines, loss of TAP1/2 or LMP2/7 expression does not appear to be a common mechanism of immune escape in malignant melanoma.lld:pubmed
pubmed-article:9052759pubmed:languageenglld:pubmed
pubmed-article:9052759pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:citationSubsetIMlld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9052759pubmed:statusMEDLINElld:pubmed
pubmed-article:9052759pubmed:monthMarlld:pubmed
pubmed-article:9052759pubmed:issn0020-7136lld:pubmed
pubmed-article:9052759pubmed:authorpubmed-author:ZeuthenJJlld:pubmed
pubmed-article:9052759pubmed:authorpubmed-author:KirkinA FAFlld:pubmed
pubmed-article:9052759pubmed:authorpubmed-author:SeremetTTlld:pubmed
pubmed-article:9052759pubmed:authorpubmed-author:Thor...lld:pubmed
pubmed-article:9052759pubmed:issnTypePrintlld:pubmed
pubmed-article:9052759pubmed:day4lld:pubmed
pubmed-article:9052759pubmed:volume70lld:pubmed
pubmed-article:9052759pubmed:ownerNLMlld:pubmed
pubmed-article:9052759pubmed:authorsCompleteYlld:pubmed
pubmed-article:9052759pubmed:pagination582-6lld:pubmed
pubmed-article:9052759pubmed:dateRevised2007-7-24lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:meshHeadingpubmed-meshheading:9052759-...lld:pubmed
pubmed-article:9052759pubmed:year1997lld:pubmed
pubmed-article:9052759pubmed:articleTitleExpression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines.lld:pubmed
pubmed-article:9052759pubmed:affiliationDepartment of Tumor Cell Biology, Danish Cancer Society, Copenhagen.lld:pubmed
pubmed-article:9052759pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9052759pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9052759lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9052759lld:pubmed